Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs

被引：0
|
作者：
K Brookes
J Cummings
A Backen
A Greystoke
T Ward
G C Jayson
C Dive
机构：
[1] Clinical and Experimental Pharmacology Group,
[2] Paterson Institute for Cancer Research,undefined
[3] University of Manchester,undefined
[4] Translational Angiogenesis Group,undefined
[5] Paterson Institute for Cancer Research,undefined
[6] University of Manchester,undefined
来源：
British Journal of Cancer | 2010年 / 102卷
关键词：
biomarkers; angiogenesis; ELISA; method validation; stability; platelets;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1524 / 1532
页数：8
相关论文
共 17 条
  • [1] Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
    Brookes, K.
    Cummings, J.
    Backen, A.
    Greystoke, A.
    Ward, T.
    Jayson, G. C.
    Dive, C.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1524 - 1532
  • [2] Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
    J Cummings
    F Raynaud
    L Jones
    R Sugar
    C Dive
    [J]. British Journal of Cancer, 2010, 103 : 1313 - 1317
  • [3] Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
    Cummings, J.
    Raynaud, F.
    Jones, L.
    Sugar, R.
    Dive, C.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (09) : 1313 - 1317
  • [4] 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use
    Backen, A. C.
    Cummings, J.
    Mitchell, C.
    Jayson, G.
    Ward, T. H.
    Dive, C.
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2009, 342 (1-2) : 106 - 114
  • [5] Anti-angiogenic drugs:: from bench to clinical trials
    Quesada, Ana R.
    Munoz-Chapuli, Ramon
    Medina, Miguel A.
    [J]. MEDICINAL RESEARCH REVIEWS, 2006, 26 (04) : 483 - 530
  • [6] Measuring soluble biomarkers in clinical trials: do tiered approaches to the analysis and validation of assays provide an answer to the fit-for-purpose challenge?
    Hucker, Richard
    Watson, Carl
    James, Ian
    Vincent, Scott
    Muirhead, David
    [J]. BIOANALYSIS, 2014, 6 (05) : 605 - 609
  • [7] Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment
    Wei, Xia-wei
    Zhang, Zhi-rong
    Wei, Yu-Quan
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (09) : 1181 - 1192
  • [8] Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation
    Kruizinga, M. D.
    Stuurman, F. E.
    Exadaktylos, V
    Doll, R. J.
    Stephenson, D. T.
    Groeneveld, G. J.
    Driessen, G. J. A.
    Cohen, A. F.
    [J]. PHARMACOLOGICAL REVIEWS, 2020, 72 (04) : 899 - 909
  • [9] Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application
    Nielsen, Ole H.
    Grimm, Daniela
    Wehland, Markus
    Bauer, Johann
    Magnusson, Nils E.
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2015, 13 (03) : 381 - 391
  • [10] "Fit-for-Purpose" Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies
    Wang, Jin
    Lee, Jean
    Burns, Daniel
    Doherty, David
    Brunner, Laura
    Peterson, Mark
    DeSilva, Binodh
    [J]. AAPS JOURNAL, 2009, 11 (02): : 385 - 394
12